Pfizer Inc. [NYSE: PFE] price surged by 0.84 percent to reach at $0.29. The company report on February 13, 2021 that U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The first and only FDA-approved intravenous immunoglobulin with two maintenance dosing options for CIDP.
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for PANZYGA® (Immune Globulin Intravenous [Human] – ifas 10% Liquid Preparation) to treat adult patients with a rare neurological disease of the peripheral nerves called chronic inflammatory demyelinating polyneuropathy (CIDP). PANZYGA is the only intravenous immunoglobulin (IVIg) with two FDA-approved maintenance dosing options for CIDP, helping to meet the clinical needs of patients. PANZYGA can also be administered at infusion rates up to 12 mg/kg/min.
A sum of 25578646 shares traded at recent session while its average daily volume was at 44.55M shares. Pfizer Inc. shares reached a high of $34.95 and dropped to a low of $34.36 until finishing in the latest session at $34.72.
The one-year PFE stock forecast points to a potential upside of 15.5. The average equity rating for PFE stock is currently 2.60, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Pfizer Inc. [PFE]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PFE shares is $41.09 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PFE stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
DZ Bank have made an estimate for Pfizer Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on February 04, 2021. While these analysts kept the previous recommendation, RBC Capital Mkts dropped their target price from $43 to $42. The new note on the price target was released on December 16, 2020, representing the official price target for Pfizer Inc. stock. Previously, the target price had yet another raise to $40, while Goldman analysts kept a Neutral rating on PFE stock.
The Average True Range (ATR) for Pfizer Inc. is set at 0.58, with the Price to Sales ratio for PFE stock in the period of the last 12 months amounting to 4.02. The Price to Book ratio for the last quarter was 2.96, with the Price to Cash per share for the same quarter was set at 1.90. Price to Free Cash Flow for PFE in the course of the last twelve months was 41.84 with Quick ratio for the last quarter at 1.10.
PFE Stock Performance Analysis:
Pfizer Inc. [PFE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.57. With this latest performance, PFE shares dropped by -5.81% in over the last four-week period, additionally sinking by -4.02% over the last 6 months – not to mention a drop of -0.79% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PFE stock in for the last two-week period is set at 34.43, with the RSI for the last a single of trading hit 32.53, and the three-weeks RSI is set at 37.36 for Pfizer Inc. [PFE]. The present Moving Average for the last 50 days of trading for this stock 37.31, while it was recorded at 34.74 for the last single week of trading, and 36.83 for the last 200 days.
Insight into Pfizer Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Pfizer Inc. [PFE] shares currently have an operating margin of +20.90 and a Gross Margin at +79.26. Pfizer Inc.’s Net Margin is presently recorded at +16.67.
Pfizer Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.40.
PFE Stock EPS
With the latest financial reports released by the company, Pfizer Inc. posted 0.8/share EPS, while the average EPS was predicted by analysts to be reported at 0.73/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PFE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Pfizer Inc. go to 3.60%.
Pfizer Inc. [PFE] Insider Position Details
There are presently around $127,920 million, or 69.00% of PFE stock, in the hands of institutional investors. The top three institutional holders of PFE stocks are: VANGUARD GROUP INC with ownership of 447,958,747, which is approximately -0.691% of the company’s market cap and around 0.05% of the total institutional ownership; BLACKROCK INC., holding 396,973,512 shares of the stock with an approximate value of $13.78 billion in PFE stocks shares; and STATE STREET CORP, currently with $10.04 billion in PFE stock with ownership of nearly -3.282% of the company’s market capitalization.
Positions in Pfizer Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 1,460 institutional holders increased their position in Pfizer Inc. [NYSE:PFE] by around 114,342,304 shares. Additionally, 1,064 investors decreased positions by around 230,143,440 shares, while 195 investors held positions by with 3,339,841,196 shares. The mentioned changes placed institutional holdings at 3,684,326,940 shares, according to the latest SEC report filing. PFE stock had 230 new institutional investments in for a total of 14,157,521 shares, while 109 institutional investors sold positions of 16,553,562 shares during the same period.